Human Andrology

Skip Navigation LinksHome > June 2014 - Volume 4 - Issue 2 > Nonresponse to phosphodiesterase 5 inhibitors in erectile dy...
Text sizing:
Human Andrology:
doi: 10.1097/01.XHA.0000446499.94391.31
Review article

Nonresponse to phosphodiesterase 5 inhibitors in erectile dysfunction. Part 1: related factors

Abdel-Hamid, Ibrahim A.a; Abo-Aly, Mohamed A.b; Elsaied, Moustafa A.a

Collapse Box


Although oral phosphodiesterase 5 inhibitors (PDE5-Is) are highly efficacious for many men with erectile dysfunction (ED), a relatively large subset of ED patients who do not respond to PDE5-Is has been identified. This review assessed the possible factors related to nonresponse to PDE5-Is in patients with ED. The review was based on previously published studies and involved a PubMed–MEDLINE search from January 1998 (year of sildenafil’s approval) through to January 2014. To achieve the maximum sensitivity of the search strategy and identify all studies, we combined ‘oral phosphodiesterase 5 inhibitors’ or ‘sildenafil’ or ‘vardenafil’ or ‘tadalafil’ as Medical Subject Headings (MeSH) terms or keywords with ‘non-response’ or ‘response’ or ‘failure’ or ‘erectile dysfunction’ or ‘etiologic factors’. Several factors are possibly related to nonresponse, including inadequate administration, instructions/inappropriate use, misdiagnosis, uncontrolled comorbidities, severe ED, psychosocial issues/personal-related factors, partner-related factors, and pharmacogenetic/pharmacogenomic factors. Real nonresponders mostly suffer from severe end-organ failure or pharmacogenetic factors, whereas correctable factors are seen as the cause in pseudononresponders. Awareness and early recognition of the etiological factors of nonresponse to PDE5-Is can help clinicians improve the treatment outcome.

© 2014 Human Andrology


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.